Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2011;2011:36-42. doi: 10.1182/asheducation-2011.1.36.

Impact of genetic features on treatment decisions in AML.

Author information

1
Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. hartmut.doehner@uniklinik-ulm.de

Abstract

In recent years, research in molecular genetics has been instrumental in deciphering the molecular pathogenesis of acute myeloid leukemia (AML). With the advent of the novel genomics technologies such as next-generation sequencing, it is expected that virtually all genetic lesions in AML will soon be identified. Gene mutations or deregulated expression of genes or sets of genes now allow us to explore the enormous diversity among cytogenetically defined subsets of AML, in particular the large subset of cytogenetically normal AML. Nonetheless, there are several challenges, such as discriminating driver from passenger mutations, evaluating the prognostic and predictive value of a specific mutation in the concert of the various concurrent mutations, or translating findings from molecular disease pathogenesis into novel therapies. Progress is unlikely to be fast in developing molecular targeted therapies. Contrary to the initial assumption, the development of molecular targeted therapies is slow and the various reports of promising new compounds will need to be put into perspective because many of these drugs did not show the expected effects.

PMID:
22160010
DOI:
10.1182/asheducation-2011.1.36
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center